Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy

N/ACompletedNCT01319318

Allergan25 enrolled

Overview

This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Vitrectomy

Interventions

Pars Plana VitrectomyPROCEDURE

Pars plana vitrectomy performed in study eye on Day 0.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Require pars plana vitrectomy in at least 1 eye * Best corrected visual acuity in the study eye between 20/400 and 20/40 Exclusion Criteria: * Use of any NSAIDs (topical or systemic) within 14 days * Use of topical or systemic steroids within 30 days * Active eye infection in either eye * Any eye surgery within 6 months * Prior pars plana vitrectomy, YAG capsulotomy or uveitis

Locations (1)

Unnamed facility

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Percentage of Participants With Vitreous Cell Count of 0

The study eye was dilated and the investigator used an instrument to count the number of visible cells in the vitreous, the jelly-like fluid that fills the back of the eye, using the following scale: 0 (no cells) best, +1 (1-10 cells), +2 (11-30 cells), +3 (31-50 cells) and +4 (\>50 cells) worst.

Time frame: Week 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.